Close

SGN-CD19A(Denintuzumab mafodotin) (TAB-891)

DESCRIPTION CATALOG # SIZE PRICE
Anti-Human CD19 Therapeutic Antibody TAB-891 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant humanized antibody expressed in CHO binding to human CD19. SGN-CD19A(Denintuzumab mafodotin) is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.
  • Target
  • CD19
  • Type
  • IgG1 - kappa
  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in ELISA, FC, IP, FuncS, IF, Neut, ICC and most other immunological methods.
  • Predicted N terminal
  • QVQLQESG
  • Molecular Weight
  • Approximately 150 kDa
  • Purity
  • >95.0% as determined by analysis by RP-HPLC.
  • Size
  • 1mg
  • Storage
  • At -20°C for one year.

BACKGROUND

  • Introduction
  • SGN-CD19A(Denintuzumab mafodotin) is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.
  • Function
  • receptor signaling protein activity;
  • Synonyms
  • CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;

Related Products

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us